| Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test AS Drake, B Weinstock-Guttman, SA Morrow, D Hojnacki, FE Munschauer, ... Multiple Sclerosis Journal 16 (2), 228-237, 2010 | 327 | 2010 |
| Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline SA Morrow, A Drake, R Zivadinov, F Munschauer, B Weinstock-Guttman, ... The clinical neuropsychologist 24 (7), 1131-1145, 2010 | 303 | 2010 |
| Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis B Weinstock-Guttman, R Zivadinov, N Mahfooz, E Carl, A Drake, ... Journal of neuroinflammation 8, 1-7, 2011 | 272 | 2011 |
| Quercetin and interferon-β modulate immune response (s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients Z Sternberg, K Chadha, A Lieberman, D Hojnacki, A Drake, P Zamboni, ... Journal of Neuroimmunology 205 (1-2), 142-147, 2008 | 123 | 2008 |
| Benchmarks of meaningful impairment on the MSFC and BICAMS RHB Benedict, AS Drake, LN Irwin, SE Frndak, KA Kunker, AL Khan, ... Multiple Sclerosis Journal 22 (14), 1874-1882, 2016 | 81 | 2016 |
| Differential effects of aging on motor and cognitive functioning in multiple sclerosis S Roy, S Frndak, AS Drake, L Irwin, R Zivadinov, B Weinstock-Guttman, ... Multiple Sclerosis Journal 23 (10), 1385-1393, 2017 | 64 | 2017 |
| Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-β Z Sternberg, K Chadha, A Lieberman, A Drake, D Hojnacki, ... Journal of Neuroinflammation 6, 1-8, 2009 | 64 | 2009 |
| Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity Z Sternberg, B Weinstock-Guttman, D Hojnacki, P Zamboni, R Zivadinov, ... Multiple Sclerosis Journal 14 (6), 759-763, 2008 | 63 | 2008 |
| Recovery of cognitive function after relapse in multiple sclerosis RHB Benedict, J Pol, F Yasin, D Hojnacki, C Kolb, S Eckert, B Tacca, ... Multiple Sclerosis Journal 27 (1), 71-78, 2021 | 55 | 2021 |
| Impact of pharmacotherapy on cognitive dysfunction in patients with multiple sclerosis S Roy, RHB Benedict, AS Drake, B Weinstock-Guttman CNS drugs 30 (3), 209-225, 2016 | 51 | 2016 |
| Remote assessment of verbal memory in MS patients using the California Verbal Learning Test LF Barcellos, KH Bellesis, L Shen, X Shao, T Chinn, S Frndak, A Drake, ... Multiple Sclerosis Journal 24 (3), 354-357, 2018 | 39 | 2018 |
| Longitudinal personality change associated with cognitive decline in multiple sclerosis S Roy, A Drake, T Fuchs, MG Dwyer, R Zivadinov, BP Chapman, ... Multiple Sclerosis Journal 24 (14), 1909-1912, 2018 | 38 | 2018 |
| Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment? S Roy, AS Drake, MB Eizaguirre, R Zivadinov, B Weinstock-Guttman, ... Multiple Sclerosis Journal 24 (2), 205-213, 2018 | 32 | 2018 |
| High-mobility group box 1 in multiple sclerosis Z Sternberg, D Sternberg, T Chichelli, A Drake, N Patel, C Kolb, K Chadha, ... Immunologic research 64, 385-391, 2016 | 31 | 2016 |
| Preliminary investigation of cognitive function in aged multiple sclerosis patients: challenges in detecting comorbid Alzheimer’s disease S Roy, A Drake, S Snyder, B Cline, A Khan, T Fuchs, R Zivadinov, ... Multiple Sclerosis and Related Disorders 22, 52-56, 2018 | 27 | 2018 |
| Negative work events reported online precede job loss in multiple sclerosis SE Frndak, LN Irwin, VM Kordovski, K Milleville, C Fisher, AS Drake, ... Journal of the neurological sciences 357 (1-2), 209-214, 2015 | 27 | 2015 |
| Dalfampridine benefits ambulation but not cognition in multiple sclerosis N Satchidanand, A Drake, A Smerbeck, D Hojnacki, C Kolb, K Patrick, ... Multiple Sclerosis Journal 26 (1), 91-98, 2020 | 25 | 2020 |
| Stable neuropsychiatric status in multiple sclerosis: a 3-year study S Roy, J Rodgers, AS Drake, R Zivadinov, B Weinstock-Guttman, ... Multiple Sclerosis Journal 22 (4), 569-574, 2016 | 20 | 2016 |
| Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects Z Sternberg, T Chichelli, D Sternberg, D Hojnacki, A Drake, S Liu, Q Hu, ... Atherosclerosis 231 (2), 411-420, 2013 | 19 | 2013 |
| Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis Z Sternberg, D Sternberg, A Drake, T Chichelli, J Yu, D Hojnacki Journal of Neuroimmunology 274 (1-2), 197-201, 2014 | 16 | 2014 |
